All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Approved Oncology Drugs in Clinical Development in SWITZERLAND

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Roche's Tecentriq nabs solo OK in first-line lung cancer

Contact the Supplier

Lead Product(s): Atezolizumab

Therapeutic Area: Oncology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Approval based on the Phase III IMpower110 study showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy.

Debiopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

9th Annual HPAPI Summit 2020

Participation Not Confirmed

Update your events

Knight Partners With Debiopharm for the Commercialization of Trelstar® in Canada

Contact the Supplier

Lead Product(s): Triptorelin

Therapeutic Area: Oncology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Knight Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 08, 2020

Details:

The agreement grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada.